YM 58997
Latest Information Update: 09 Aug 2002
Price :
$50 *
At a glance
- Originator Yamanouchi
- Class Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 27 Oct 1999 New profile
- 27 Oct 1999 Phase-I clinical trials for Asthma in Japan (PO)